Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Announces Q1 2025 Financial Results and Key Approvals
Summary
Alnylam Pharmaceuticals, Inc. reported its financial results for the first quarter of 2025, showing a 28% increase in global net product revenues to $469 million. The company received U.S. FDA approval for AMVUTTRA to treat ATTR-CM, and approval for Qfitlia to prevent or reduce bleeding episodes in hemophilia patients. Alnylam reiterated its 2025 financial guidance with combined net product revenues expected between $2,050 million and $2,250 million.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement